Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A total of 65 patients with food allergy which manifested primarily by disorders of the gastrointestinal tract, bronchi and skin were placed under observation. The patients were administered sodium chromoglycate (nalcrom) per os in a dose of 200 mg 4 times a day for 2-3 weeks, in part of cases up to 3 months and even up to 1-1.5 year. The skin manifestations of allergy (pruritus, urticaria, Quincke's edema, and eczematous rash), abdominal pain, diarrhea, vomiting, bronchospasm, rhinitis, and conjunctivitis disappeared. At the same time the majority of the patients demonstrated the reduction of the intensity of skin responses to the administration of different food antigens, the decrease of the antibody titer in blood serum in response to food antigens, and of the IgE content in blood. The side effects (nausea, heartburn, intensification of skin itch and abdominal pain) were noted in 4 cases.
 ...
PMID:[Treatment of patients with food allergy using Nalcrom]. 249 73

In an open study, the clinical efficacy of sulglycotide was tested in patients with non-ulcerous dyspepsia (NUD). Outpatients with dyspeptic symptoms of at least 3-months' standing were entered into the study; diagnosis was based on history, clinical findings and endoscopy. Forty-four patients could be evaluated after 8 weeks' treatment with sulglycotide (200 mg t.i.d. orally). Treatment results were checked endoscopically and on the basis of changes in subjective symptoms (heartburn, epigastric pain, nausea, vomiting, postprandial sense of fullness, eructations, regurgitation, all of which were quantified on an analogic scale from 0 = absent to 3 = intense). Treatment with sulglycotide led to marked and significant improvement of clinical symptoms of NUD (p less than 0.05 vs. baseline) and of macroscopic endoscopic findings recorded at entry. It is concluded that sulglycotide is a valid therapeutic choice for patients suffering from NUD.
 ...
PMID:[Sulglicotide in non-ulcerous dyspepsia]. 252 69

A 57-year-old white man presenting frequent recurrent chest and precordial pain, heartburn (pyrosis) and post-prandial vomiting for the previous 33 years (one to two years after Bilroth II gastrectomy) was submitted to cardiovascular, endoscopic, radiologic and biochemical studies with negative results. Doctors recommended surgical operation because of an excessively long afferent loop, Several biologic markers were performed at our hospital (intestinal pharmacomanometry, i.m. clonidine test, plasma neurotransmitters plus hormones, oral glucose tolerance test, plasma insulin, etc.), revealing an autonomic nervous system (ANS) imbalance characterized by hyperactivity of the cholinergic plus hypoactivity of the noradrenergic central system. Psychiatric evaluation demonstrated Dysthymic Depression. Treatment with a small daily dose of amitriptyline (a drug which enhances central noradrenergic activity and exerts powerful anticholinergic effects) suppressed symptoms, normalized physiological plus hormonal plus neurochemical parameters and made depressive manifestations disappear. The results suggest that the ANS imbalance was related to depressive syndrome and potentiated by neurohumoral disorders depending on duodenal and jejunal exclusion, and on intestinal post-prandial hyper-osmolarity.
 ...
PMID:Recurrent gastroesophageal symptoms and precordial pain in a gastrectomized man improved by amitriptyline. Physiologic, metabolic, endocrine, neurochemical and psychiatric findings. 257 35

The majority of patients receiving cisplatin at a dose of 120 mg/m2 experience delayed nausea and vomiting occurring between 24 and 120 hours after chemotherapy administration. Ninety-one patients who were receiving cisplatin (120 mg/m2) as initial chemotherapy were entered into this double-blind trial. All patients received intravenous (IV) metoclopramide, dexamethasone, and lorazepam for the control of acute emesis during the period from 0 to 24 hours after cisplatin. Patients were then randomized to one of three treatment regimens: placebo; oral dexamethasone, 8 mg twice daily for two days, then 4 mg twice daily for two days; or the combination of oral metoclopramide, 0.5 mg/kg four times daily for four days, plus oral dexamethasone administered as above. Forty-eight percent of individuals who received the two-drug combination of metoclopramide plus dexamethasone experienced delayed vomiting as opposed to 65% who were administered dexamethasone alone and 89% who received placebo (P = .006). Scores assessing the severity of delayed nausea and vomiting were consistently worse in individuals receiving placebo. The incidences of sleepiness, restlessness, heartburn, hiccoughs, loose bowel movements, insomnia, and acute dystonic reactions did not differ significantly among the three regimens and were mild and self-limited. The two-drug combination of oral metoclopramide plus dexamethasone is well tolerated, safe, and more effective than dexamethasone alone or placebo in controlling delayed vomiting following cisplatin.
 ...
PMID:Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. 264 36

A retrospective cohort study determined the risk and cost of gastrointestinal side effects associated with the use of nonsteroidal anti-inflammatory drugs for an at-risk period from January 1, 1985, through March 31, 1985. Overall relative risk, adjusted for sex and race, was 2.52 (95% confidence interval, 2.25 to 2.82) and varied from 1.64 (95% confidence interval, 0.92 to 2.91) for duodenal ulcer to 3.27 (95% confidence interval, 1.40 to 7.66) for gastrointestinal bleeding. After deleting cases with a history of steroid or anticoagulant use or an alcohol-related diagnosis, adjusted relative risk was 2.58 (95% confidence interval, 2.29 to 2.90) and varied from 1.45 (95% confidence interval, 0.73 to 2.89) for all other cases of peptic ulcer to 2.37 (95% confidence interval, 1.26 to 4.46) for disorders of stomach function. There was a bimodal distribution of expenditures of Medicaid-paid gastrointestinal side effects. Most patients had low hospitalization costs, but an important minority had high hospitalization costs. Median ambulatory treatment costs during the 3-month study period for persons with gastrointestinal side effects was $27 and varied from $14 for those diagnosed as having nausea, vomiting, or heartburn to $393 for those diagnosed as having gastrointestinal bleeding. Median inpatient costs were $2006 and ranged from $1487 for persons with nausea, vomiting, or heartburn to $2486 for those with duodenal ulcer. For patients who had undergone an inpatient surgical procedure other than endoscopy alone, median hospital costs were $7209. An approximately twofold increase in payment for the same services would be expected if private third-party payers were responsible for the bill.
 ...
PMID:Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. 271 96

Long-term oesophageal pH monitoring has become the preferred technique for detection and quantification of gastro-oesophageal reflux (GOR). The most obvious advantages of pH monitoring are the duration of the investigation, the possibility of being able to relate "events" (emesis, heartburn, apnoea) to pH changes (and to study "occult GOR"), the physiological conditions in which the data are recorded (sleep, work), and the possibility of repeating the investigation in treatment conditions. However, it has been reported that the accuracy of pH monitoring is no higher than 90%, because the intermittent presence of acid in the oesophagus is only one of the various abnormalities in the syndrome of GOR. A tremendous number of technique- (pH monitoring system, type of electrode, location of the electrode) and patient-related factors influence pH data. Age, position (both for adults and for infants), duration of the investigation (day/night), feeding and drugs are patient-related factors. Finally, the question arises (which is still unanswered) whether the indication for pH monitoring should be considered in the interpretation of the data: are the same criteria valid for GOR in children presenting with emesis and oesophagitis as for children with GOR resulting in chronic respiratory disease or "near-miss sudden infant death syndrome".
 ...
PMID:PH monitoring in children. 272 3

Analysis of clinical data obtained in a double-blind randomized study, which compared liquid antacid (neutralizing capacity 120 mmol per day) with 1 g cimetidine in the treatment of 125 patients with gastric ulcer, revealed that, before starting treatment, 71% of the patients complained of epigastric pain, approximately 50% of bloating, and approximately 30% of nausea, heartburn, constipation or vomiting. Epigastric pain before treatment was significantly more frequent in patients with large ulcers (P less than 0.05) and in patients with ulcers unhealed after 4 weeks of therapy (P less than 0.05). This finding was the result of a highly significant correlation between diurnal epigastric pain and ulcer size and delayed healing (P less than 0.005). Nocturnal pain did not correlate with prognosis. In contrast to this correlation between pain before therapy and healing, the disappearance of epigastric pain with therapy did not signify ulcer healing. Only 14 (38%) of the 37 patients with healed ulcer were free from pain after the 4 weeks of therapy, whereas 25 (49%) of the 52 patients with persistent ulcers had no pain at this time. Placebo pain tablets relieved ulcer pain effectively in more than 85% of the patients, irrespective of whether the ulcer was healing or not. The other symptoms (bloating, nausea, heartburn, constipation or vomiting) were also alleviated by 4 weeks of therapy but no correlation was found with ulcer size or prognosis. The loss of the prognostic significance of ulcer pain is probably due to a complex interaction of the trial schedule on the patient's level of consciousness.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Loss of predictive value of gastric ulcer symptoms in a randomized treatment trial. 297 76

In this double-blind multicentre trial, 127 patients on non-steroidal anti-inflammatory drugs (NSAIDs) who experienced gastrointestinal symptoms significant enough to warrant endoscopic evaluation, but without endoscopic evidence of mucosal damage, were randomized to receive cimetidine 400 mg b.d. or placebo for 4 weeks. Non-steroidal anti-inflammatory drug therapy was maintained at pre-trial doses for the duration of the study. After 4 weeks, 72% of cimetidine-treated patients experienced complete symptom resolution, as defined by a global symptom score of zero, compared with 49% on placebo. Complete disappearance of upper abdominal pain was achieved in 72% of the cimetidine-treated patients as opposed to 47% on placebo. Relief of heartburn was experienced by 87% of patients on cimetidine compared with 60% on placebo. Throughout treatment, the proportion of cimetidine-treated patients with nausea was consistently lower than in patients on placebo, while the two groups were similar with respect to disappearance of vomiting. At the completion of acute treatment, 27% of placebo-treated patients but only 12% of those on cimetidine were ineligible to continue maintenance due to persisting gastrointestinal symptoms. Patients who were symptom-free and required continuation of NSAID therapy were followed for 6 months during which they were re-randomized to receive cimetidine 400 mg nocte or placebo. Of the 105 patients included in this maintenance treatment phase of the study, 11% of the cimetidine-treated patients and 10% of those on placebo experienced relapse of symptoms. However, the mean time to relapse was 120 days with cimetidine compared with 35 days with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study. 297 86

In 9 out of 11 subjects with upper digestive dyspepsia: pyrosis, nausea, emesis, bloating, with negative roentgenological findings, a radioisotopic test detected a delayed gastric emptying. The investigation was based on a 500 ml saline meal including lmCi (3.7 MBq) 113m In-DTPA. For the sequential detection of the radioactivity in front of the epigastric area a gammacamera was used. This was linked to a microcomputer processing the histograms of the curves and estimating the half-time of the gastric emptying (normal value 8-25 min). The results suggest the need for prokinetic drugs in the management of symptoms due to functional pathology.
 ...
PMID:Delayed gastric emptying in rx-negative dyspepsia. 313 74

Twelve partially gastrectomized subjects who have consecutively undergone total biliary diversion for severe bilious vomiting were studied before and after operation in order to assess the effects of surgery on gastric histology and enterogastric reflux. Before and six months after operation, the following protocol was performed: (1) blood examinations including serum basal gastrin; (2) endoscopy with multiple gastric biopsies; and (3) quantitation of bile acids in the gastric aspirate. Of the preoperative symptoms, bilious vomiting and heartburn completely disappeared postoperatively in all the subjects. Fasting bile reflux was significantly reduced (bile reflux was annulled in six and considerably lowered in the remaining six subjects), and erythema of the gastric mucosa completely disappeared in all the subjects after diversion. Among histological findings, while a significant regression of foveolar hyperplasia was found both in the perianastomotic area and in the body of gastric remnant, none of the other aspects identifiable in postgastrectomy gastric mucosa (chronic gastritis changes included) were affected by diversion. These results show that biliary diversion is effective in correcting reflux, bilious vomiting, erythema, and foveolar hyperplasia of the gastric mucosa and confirm the suggested relationship between bile reflux and gastric foveolar hyperplasia.
 ...
PMID:Short-term effects of bile diversion on postgastrectomy gastric histology. 316


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>